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Aim To evaluate the association between the use of dipep-
tidyl peptidase-4 inhibitors (DPP4I) and clinical and labora-
tory findings of bullous pemphigoid (BP) in patients treat-
ed at the European Reference Network – Skin Reference 
Centre in Croatia.
Methods This retrospective study enrolled 82 patients 
treated for BP at the Department of Dermatovenereology, 
University Hospital Center Zagreb from January 2015 to 
December 2019. Clinical features of BP, presence of comor-
bidities, and laboratory findings of anti-BP antibodies and 
eosinophilia were analyzed in three groups of BP patients: 
1) diabetes mellitus (DM) type II patients treated with DP-
P4I, 2) DM type II patients not treated with DPP4I, and 3) 
non-DM type II patients.
Results The average age and anti-BP180 titer were similar 
in all three groups. DPP4I group had a slightly lower eo-
sinophil level in both peripheral blood (4.89%) and biopsy 
specimens (87.5%), but the difference was not significant. 
The prevalence of inflammatory BP in DPP4I group was 
76.5%. DPP4I group had significantly higher percentage 
of patients with chronic renal failure and dementia (52.9% 
and 11.8%, respectively) compared with non-DPP4I DM 
(14.3% and 0%, respectively) and non-DM type II patients 
(15.7% and 0%, respectively).
Conclusion BP patients treated with DPP4I and those not 
treated with DPP4Is did not significantly differ in laborato-
ry findings. However, DPP4I treatment was associated with 
an inflammatory subtype of BP and a higher prevalence of 
dementia and chronic renal failure. These findings warrant 
further research into the association of BP and DM with de-
mentia and chronic renal failure.
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Bullous pemphigoid (BP) is a skin-directed autoimmune blis-
tering disease, which most commonly affects the elderly 
during the eighth decade of life (1). The incidence of BP var-
ies from 2.5 to 42.8 cases per million a year and is increasing 
(1-4). The reason for the increasing incidence is unknown, but 
it is presumed to be population aging (1,2). In the population 
older than 80, the incidence is nearly 150-330 cases/million/y 
(3,5,6), while in the population older than 90 it is 398 cases/
million/y among men and 87 new cases/million among 
women (5,7). Current data show no gender preponderance 
– some authors found an increased incidence among wom-
en and some among men (4,5,7). BP is characterized by the 
presence of autoantibodies against structural hemidesmo-
somal proteins BP180 (BPAG 2) and BP230 (BPAG1), which are 
part of the basement membrane zone (BMZ). Most autoan-
tibodies bind to the extracellular, non-collagenous NC16A 
domain of BP180, which is the dominant antigenic epitope 
in BP. Autoantibodies are mostly of IgG type, with predomi-
nantly IgG1 and IgG3 subtype, followed by IgG4 subtype. 
IgA and IgE autoantibodies can also be detected (6). In the 
early, non-bullous, phase of the disease, IgE antibody exerts 
its pathogenic role through the well-known mechanism of 
mast cell degranulation, which clinically presents as urticarial 
lesions and pruritus (8). High IgE levels were found in 70% of 
BP patients before starting the therapy and are linked to BP 
resistance to classical therapeutic options (8,9).
The diagnosis of BP is based on histopathology, direct im-
munofluorescence (DIF), indirect immunofluorescence, 
and enzyme-linked immunosorbent assay (ELISA). ELISA 
for the detection of circulating anti-BP 180 and anti-BP 230 
autoantibodies can be used not only for the diagnosis but 
also for disease activity follow-up. Nowadays, assays for IgE 
anti-BP antibodies detection are commercially available for 
ELISA, which opens new possibilities for modern treatment 
modalities (10).
The etiology of BP is still unclear. Autoreactivity in BP is 
linked to the genetic factor HLA-DQß1*0301 (11-14). Fac-
tors that also participate in the pathogenesis of BP are Th1 
and Th2 immune responses, as well as Th17 pathway acti-
vation (10). Only in a minority of predisposed individuals, 
the disease onset is connected to risk factors, such as older 
age, neurological disease, viral infections, physical factors 
(like sunburns or ionizing radiation), and drugs (11-13).
Since BP most commonly affects elderly patients, it is as-
sociated with a higher number of comorbidities (cardio-
vascular disease, neurological diseases, ie, dementia and 
Parkinson disease, and diabetes mellitus) and a higher 
mortality rate (2,13-18). Also, the elderly population, owing 
to multiple comorbidities and malignancies, is also exposed 
to polypharmacy, which can trigger the development of BP.
The relationship between BP and diabetes mellitus (DM) 
has been well known for decades (14,19,20). DM is one of 
the most common comorbidities, as well as a significant risk 
factor of one-year mortality (14). Still, the number of DM pa-
tients with BP has been increasing (19,21), and the increase 
has been attributed to an increased use of dipeptidyl pep-
tidase-4-inhibitors (DPP4I or gliptins) (14,22,23). DPP4 is a 
cell-surface serine exopeptidase, a part of prolyl oligopep-
tidase family, found in various tissues (24). In the immune 
system, DPP4 is found on T lymphocytes and on activated 
NK cells, and it is clustered as CD26 (14,24,25). DPP4 inacti-
vates many proinflammatory cytokines, and the inhibition 
of DPP4 may be implicated in complex regulation of inflam-
matory response (25). The exact mechanism of BP develop-
ment induced by DPP4I is unknown, but there are some 
drug-dependent differences in clinical and pathological 
features (14). Published studies showed data inconsistency 
regarding predominant inflammatory vs non-inflammatory 
clinical features of BP induced by DPP4I (14,25,26).
DPP4I include vildagliptin, sitagliptin, saxagliptin, linaglip-
tin, and alogliptin. Vildagliptin is most commonly associ-
ated with the development of BP, followed by linagliptin 
(22,23,26-28). Thus, the relationship between BP and those 
two gliptins was mostly studied, while other drugs from 
the family have been investigated to a lesser extent.
Since the differences between patients with DPP4I-in-
duced BP and those with DPP4I-non-induced BP are still 
not clear, the aim of our study was to evaluate the associa-
tion between the use of DPP4I and clinical and laboratory 
findings of BP in patients treated at the European Refer-
ence Network – Skin Reference Centre in Croatia.
PATIENTS AND METHODS
This retrospective study enrolled all patients (N = 82) treat-
ed for BP from January 2015 to December 2019 at the 
Department of Dermatovenereology, University Hospital 
Centre Zagreb. Patients’ records were obtained from the 
Hospital Information System. Patients were diagnosed ac-
cording to the International Classification of Diseases, 10th 
revision, code L12.0.
The definite diagnosis of BP was made by a dermatologist 
based on clinical findings, histopathology, DIF, and ELISA 
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testing for antibodies against BP 180 and BP 230. For fur-
ther analyses we used data for anti-BP 180 only as it has 
higher importance in diagnosis and follow-up than anti-BP 
230. The anti-BP 180 (anti-BP 180 NC 16A) antibody titer 
positivity was defined as ≥20 RU/mL (RU = relative unit).
The collected data included the age at BP onset, sex, anti-
BP180 antibodies, the presence of DM type II, chronic renal 
failure, dementia or neurological disease, and DPP4I treat-
ment before the onset of BP.
We divided BP patients into three groups: 1) DM type II 
patients treated with DPP4I (DPP4I group); 2) DM type II 
patients not treated with DPP4I (non-DPP4I group); and 
3) non-DM type II patients. Based on clinical data, we dis-
tinguished between inflammatory and non-inflammatory 
BP type. Also, based on diagnostic evaluation, we assessed 
peripheral eosinophilia and eosinophilia in histopathol-
ogy specimens to examine if DPP4I-induced BP differed 
from non-DPP4I induced BP, as shown by other studies 
(8,26,29). This study was approved by the Ethics Commit-
tee of University Hospital Centre Zagreb (02/21A) and was 
performed in accordance with the principles of the Decla-
ration of Helsinki.
Statistical analysis
The normality of the distribution of quantitative variables 
was tested with the Kolmogorov-Smirnov test. The Kruskal-
Wallis test was used to assess the difference in the age of 
onset, peripheral eosinophilia, and anti-BP180 antibody titer 
between the groups. The Pearson χ2 test was used to test the 
differences in the frequencies of patients older than 65 years 
at the time of diagnosis, sex, hospitalization, systemic steroid 
use, eosinophils in the biopsy, positive anti-BP180 antibody, 
chronic renal failure, dementia, and neurodegenerative dis-
eases between the groups. The level of significance was set 
at P < 0.05. The statistical analysis was performed with TIBCO 
Statistica 13 (TIBCO Software Inc, Palo Alto, CA, USA).
RESULTS
DPP4I group included 17 patients (20.7%), non-DPP4I DM 
group 14 patients (17.1%), and non-DM group 51 patients 
(62.2%). The groups did not differ in the median age (75.5 
years in non-DPP4I, 74.0 in DPP4I group, and 74.0 in the 
non-DM group; P = 0.555). All patients in the DPP4I group 
were older than 65 years (100%). DPP4I group had a slight-
ly lower level of eosinophils in both peripheral blood (me-
dian 2.6%, IQR 1.0-7.0) and biopsy specimens (87.5%) in 
comparison with the other two groups, but the difference 
was not significant (P = 0.384).
DPP4I group had significantly higher percentage of pa-
tients with chronic renal failure and dementia (52.9% and 
11.8%, respectively) compared with non-DPP4I DM group 
(14.3% and 0%, respectively) and non-DM type II patients 
(15.7% and 0%, respectively) (P < 0.005) (Table 1).
TABLE 1. Clinical characteristics of patients with bullous pemphigoid without and with type-2 diabetes mellitus, treated and not 
treated with dipeptidyl peptidase-4 inhibitors (DPP4I)II
Non-DPP4I DM 
patients (n = 14)
DPP4I treated DM 
patients (n = 17)
Non-DM 
patients (n = 51) p
Average age of onset in years (median, interquartile range)  75.5 (69-81)  74.0 (71-81)  74.0 (66-80) 0.555*
Older than 65 years at the time of diagnosis, n (%)  13 (92.9)  17 (100.0)  45 (88.2) 0.316†
Sex ratio (male:female)   7:7   8:9  18:33 0.496†
Hospitalization, n (%)   9 (64.3%)  13 (76.5)  35 (68.6) 0.745†
Systemic steroid use, n (%)  14 (100.0)  17 (100.0)  51 (100.0) 0.144†
Eosinophils in biopsy, n (%)‡  10 (90.9)  14 (87.5)  43 (89.6) 0.957†
Percent of peripheral eosinophilia (median, interquartile range)   7.4 (2.3-12.2)   2.6 (1.0-7.0)   6.2 (1.4-13.4) 0.384*
Anti-BP180 antibody positive, n (%)§  13 (100.0)  15 (93.8)  46 (92.0) 0.573†
Anti-BP180 antibody titer (median, interquartile range), U/mL 142.9 (103.9-270.2) 139.9 (45.4-264.2) 168.2 (88.0-266.6) 0.798*
Chronic renal failure, n (%)   2 (14.3)   9 (52.9)   8 (15.7) 0.005†
Dementia, n (%)   0 (0.0)   2 (11.8)   0 (0.0) 0.020†
Neurological disorders, n (%)   2 (14.3)   4 (23.5)  10 (19.6) 0.811†
*Kruskal-Wallis test.
†Pearson χ2 test.
‡Data on 7 patients in the non-DM group, 3 patients in the non-DPP4I DM group, and 2 patients in the DPP4I group were missing.
§Data on 5 patients in the non-DM group, 1 patient in the non-DPP4I DM group, and 2 patients in the DPP4I group were missing.
IIAll of our groups were heterogeneous with high variability and a small number of participants, so the comparison of each group with another 
would not contribute to statistical significance.
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The median age of onset was 74.0 years. The most com-
monly used drug was vildagliptin, in 47.06% of patients, 
and 94.12% of patients concomitantly received another 
antidiabetic drug. The median period from starting DPP4I 
therapy to BP onset was 8.27 months. In seven patients, 
data on treatment duration were lost. In this group, 93.75% 
of patients had positive BP180 NC16A autoantibody, with 
a median titer of 139.9 RU/mL (IQR 45.4-264.2 RU/mL). 
Only 23.5% of DPP41 patients had the non-inflammatory 
subtype (Table 2).
DISCUSSION
This study showed a higher prevalence of chronic renal failure 
and dementia in patients receiving DPP4Is. These results are 
contradictory to the results of other studies, which showed 
that DPP4I treatment was associated with a lower incidence 
of dementia and may have a protective effect on renal dis-
ease progression (30,31). Our findings might be explained by 
a slightly older age in our DPP4I group in comparison to the 
other two groups and a small number of patients. In addi-
tion, older patients in our study might have neglected DM 
for some time and started treatment at a later stage, which is 
connected with the development of comorbidities.
DPP4I group in this study had a median age of 74.0 
years, which is slightly lower than in other studies 
(14,22,23,26,32,33). All the patients in this group were older 
than 65 years. Our results showed a slight, but not signifi-
cant, preponderance of women, which is in concordance 
with other findings (27).
The higher incidence of BP in the elderly may be partly 
explained by an altered immune system. Immunosenes-
cence, defined as age-related changes in the immune 
system, and its role in the development of autoimmune 
diseases among the elderly, is an important subject of sci-
entific research (34). Innate and adaptive immune systems 
change with aging. Besides immunosenescence, there is 
also cellular senescence, a process connected with the 
development of some age-related diseases. A distinct 
phenotype change of the cell is the acquisition of senes-
cence-associated secretion phenotype (SASP), which in-
cludes secreted inflammatory, growth-regulating, and 
remodeling factors. Interestingly, some of the cytokines 
up-regulated by SASP are the same cytokines involved 
in the pathomechanism of BP: interleukin (IL)-1, IL-6, and 
IL-8, tumor necrosis factor α, and matrix metalloproteinas-
es (11,35,36). Inflamm-aging can be defined as low-grade 
inflammation combined with older age. It is character-
ized by an increase in pro-inflammatory markers and cir-
culating cytokines and is associated with dementia, ath-
erosclerosis, and DM type II (36). All of these age-related 
alterations explain why BP is more frequent in the older 
TABLE 2. Characteristics of elderly diabetic patients treated with dipeptidyl peptidase-4 inhibi tors (DPP4I) who developed bullous 
pemphigoid
Sex Age DPP4I
Period from 
DPP4I to onset 
of BP (months)
Concomitant 
diabetic
drugs
Anti-BP180 an-
tibody positive 
(yes/no)
Anti-BP180/ 
antibody titer 
(U/mL)
Eosinophils in 
skin biopsy  
(yes/no)
BP subtype 
(inflammatory or 
non-inflammatory)
F 72 alogliptin 12 I yes 131.54 yes inflammatory
F 81 vildagliptin ND I + M yes 144.35 yes inflammatory
F 80 vildagliptin 12 M yes 139.9 yes inflammatory
F 79 vildagliptin  1 M + S + T yes 233.54 yes inflammatory
F 80 vildagliptin ND S + T yes 403.47 no inflammatory
M 84 sitagliptin ND S yes 353.04 yes inflammatory
M 87 linagliptin 14 M + S yes 141.95 ND non-inflammatory
M 69 vildagliptin ND M yes  45.43 yes inflammatory
M 73 linagliptin  0 M + S yes  35.69 no inflammatory
M 69 linagliptin 12 I no yes non-inflammatory
F 73 vildagliptin  3 M + I yes 264.24 yes inflammatory
M 81 vildagliptin + linagliptin  7 M + I yes  33.19 yes non-inflammatory
M 74 linagliptin ND ND ND yes inflammatory
F 69 vildagliptin 16 I yes  50.59 yes inflammatory
F 73 alogliptin 13 S yes 138.31 yes non-inflammatory
F 68 sitagliptin  1 M yes 333.10 yes inflammatory
M 81 linagliptin ND SGLT2-I yes  24.7 yes inflammatory
*ND – not determined; M – metformin; I – insulin; S – sulfonylurea; T – thiazolidinedione; SGLT2-I – sodium-glucose transport protein 2 inhibitor.
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population but also give us more insight into the connec-
tion of BP with different co-morbidities.
The disease is caused by autoantibodies directed against 
the structural components of the BMZ, particularly BP180, 
and specifically the anti-NC16A domain, which contains 
a dominant pathogenic epitope (23). It is still unknown 
what triggers the development of auto-antibodies against 
BP180. There are many gaps in the understanding of the 
etiopathogenesis of the disease, but the association of 
gliptin therapy with the development of BP has been well 
confirmed (14,22,23,26,28,32,33,37,38) (Table 3).
DPP4, or CD26, can act anti-inflammatory, by tearing and 
inactivating proinflammatory cytokines. Hence, DPP4I 
could promote an inflammatory response by activating 
cytokines, resulting in tissue damage and blister formation 
(37). It is known that eosinophils, along with neutrophils, 
produce serine proteases that damage the BMZ. Some au-
thors showed a sparse infiltration of eosinophils in BP pa-
tients treated with DPP4I (28). The exact mechanism is still 
unclear, but it has been proposed that decreased eotaxin-1 
production may act via the inhibition of eosinophil-recruit-
ing cytokines, eg, IL-13, and transforming growth factor-β1 
(28). We found a slightly lower level of eosinophils in both 
peripheral blood (4.89%) and biopsy specimens (87.5%) in 
the DPP4I group in comparison with the other two groups, 
but the result was not significant. The majority of DPP4I pa-
tients in our study (76.5%) had inflammatory BP clinical sub-
type. These results are in concordance with the studies that 
did not find a significant difference between BP patients 
who were and were not treated with DPP4I (26,38,39).
The combination of DPP4I proinflammatory effect with in-
flamm-aging may act as a major trigger in BP pathogenesis 
and its onset. Contrary to the above, it seems that autoan-
tibodies in DPP4I-induced BP are directed against other 
portions of BP180 antigen besides the NC16A domain 
(40). A recent study found that more DM patients treated 
with DPP4I had BP180-full-length and BP180 NC16A ELISAs 
than patients not treated with DPP4I. Patients with anti-full 
length BP180 IgG-positive ELISA were significantly older 
than those with anti-full length BP180 IgG-negative ELISA, 
which indicates that older age in combination with DPP4I 
treatment may be a risk factor for the development of an-
ti-full length BP180 IgG antibodies. On the other hand, a 
higher percentage of anti-full length BP 180 may indicate 
that DPP4I induce the development of BP by some still un-
known mechanism other than the BP180 NC16A epitope 
spreading (40). Our results showed no significant differ-
ence in both percentage of positive anti-BP180 antibodies 
and titer range between all three groups of patients, which 
is similar to the results of other studies (26,38,39).
There was no significant difference in hospitalization rate 
and systemic steroid administration rate between all three 
groups, which is in concordance with previous studies (23).
A meta-analysis by Phan et al (27) demonstrated a signifi-
cant association between DPP4I and BP. Among gliptins, 
vildagliptin was most strongly associated with BP develop-
ment and had the highest odds ratio, although this DPP4I 
was least frequently prescribed (22,23,26,27,30,33,41). This 
can be explained by the fact that vildagliptin is the least 
selective DPP4I and more strongly inhibits the activity of 
other DPP isoenzymes, such as DPP8 and DPP9, in a way 
that is still unknown (23). The usage of other antidiabetic 
drugs has not been shown to increase the risk for BP, so 
we did not analyze this factor (42). However, 94.12% of our 
patients treated with DPP4I received concomitant antidi-
abetic therapy. Our study showed a mean period of 8.27 
months from starting DPP4I treatment to BP onset, which 
is slightly lower than in other studies (27).
The present study has some limitations, most notably a 
small number of patients and lack of control group.
In conclusion, we found no significant differences in the 
laboratory findings (including ELISA tests and eosino-
phil count in skin biopsy and peripheral blood) of 
TABLE 3. Characteristics of eligible gliptin-associated bullous pemphigoid studies
Study Country Cases/controls Latency time (months) Age (years) Sex, male (%) Mono/multi
Varpuluoma et al (22) Finland 3397/12941 14.72 76.6 40.3 multicentric
Kawaguchi et al (23) Japan   32/136 48.4 78.9 46.8 monocentric
Kridin et al (26) Israel   82/328   / 79.1 55.3 monocentric
Benzaquen et al (32) France   61/122  8.2 79.1 49.2 multicentric
Lee et al (33) Korea  670/670   / 75.3 51.0 multicentric
Lindgren et al (38) Finland   10/17 13.4 80.3 40.0 monocentric
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BP patients treated with DPP4I and those not treated with 
DPP4Is. However, DPP4I treatment was associated with an 
inflammatory subtype of BP and a higher prevalence of 
dementia and chronic renal failure. This result warrants fu-
ture studies on the association of BP and DM with demen-
tia and chronic renal failure.
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